Restricted Research - Award List, Note/Discussion Page
Fiscal Year: 2023
1440 University of Houston (143328)
Principal Investigator: Peng,Weiyi
Total Amount of Contract, Award, or Gift (Annual before 2011): $ 32,163
Exceeds $250,000 (Is it flagged?): No
Start and End Dates: 7/7/22 - 6/30/23
Restricted Research: YES
Academic Discipline: Biology and Biochemistry
Department, Center, School, or Institute: Center for Nuclear Receptors and Cell Signaling
Title of Contract, Award, or Gift: DEVELOPMENT OF FIRST-IN-CLASS RIPK1 DEGRADERS TO IMPROVE CANCER IMMUNOTHERAPIES
Name of Granting or Contracting Agency/Entity:
Baylor College of Medicine
CFDA Link: HHS
93.395
Program Title:
n/a
CFDA Linked: Cancer Treatment Research
Note:
This proposal aims to develop novel bioactive compounds for pharmacological degradation of RIPK1, which can be a therapeutic strategy to synergize with immune checkpoint blockades (ICBs) to promote antitumor immunity. In this application, investigators with distinct expertise in chemical biology and immunology research will conduct the proposed studies. SAMs 1.1.1
Discussion: No discussion notes